Vytorin takes lead in switches of cholesterol-lowering drugs
Mid-January saw Merck and Schering-Plough’s jointly marketed statin combo Vytorin take the lead in projected switches of cholesterol-lowering indications for ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.